These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11194670)

  • 1. [Radical prostatectomy with broadened scope of indications - analysis of early experience].
    Chakarov S; Bechev R; Lazarov Z; Fachikov Ts; Rangelov S
    Khirurgiia (Sofiia); 1999; 55(3):47-8. PubMed ID: 11194670
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 3. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neoadjuvant hormonal therapy for prostate cancer].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
    Gao X; Zhou T; Tang YJ; Lu X; Sun YH
    Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
    Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
    Tunn UW; Acar O; Goldschmidt AJ
    Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical and medical treatment for localized prostate cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA response to thalidomide in patients with advanced prostate cancer.
    Leibowitz R; Tucker SJ
    Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC; Sassine AM
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.